ClinicalTrials.gg
Status unknownNCT02606955Updated Nov 17, 2015

Probing the Dry Weight by Bioimpedance: The Resistance Stabilization Test

An interventional study of BIA DW in Uremia, sponsored by Miulli General Hospital. Status unknown at 2 sites in Italy. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-11-17.

Sponsored by Miulli General Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2015), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Clinical methods are fundamental in probing the DW. They must be supported by strict BIA protocols. REST appears to be a (the) brilliant solution in solving the old problem of DW in HD patients

Read the detailed description

Probing the dry weight (DW) was largely dependent on clinical subjective estimates until recently. New bedside non-invasive tools have been developed with the aim of providing more objective information on volume status and guiding physicians in the quest for DW. Among them, bioimpedance (BIA) appears to be very promising.

Very recently, a BIA test aimed at assessing DW in hemodialysis (HD) patients has been developed, the "REsistance Stabilization Test" (REST). It is called BIA DW. Its rationale is based on the achievement of the flattening of the curve of the ratio R0/Rt (R0 is resistance at time 0 and Rt is resistance at a given time t during the HD session) of less than + 1% over 20 minutes in the presence of ongoing ultrafiltration.

Study protocol: the Clinical DW is the gold standard by definition. It is determined under strict clinical surveillance by the same attending physician. She/he will be helped by a clinical score of volume state about symptoms and signs of hypo- or hypervolemia. Then, this Clinical DW will be compared with BIA DW, as obtained after performing REST

02

Conditions studied

  • Uremia

Browse trials for

Keywords

  • Bioimpedance
  • Dry weight
  • Hemodialysis
  • Resistance
03

In context

Uremia

53 studies on the registry are indexed under Uremia; 10 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 38 interventional studies indexed under Uremia.

Browse Uremia studies →

Lead sponsor

Miulli General Hospital is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • stable uremic patients
  • thrice weekly hemodialysis treatment
  • start of hemodialysis treatment since at least 3 months

Exclusion criteria

Exclusion Criteria

  • overt edema
  • liver cirrhosis
  • cardiac failure
  • serum albumin \< 3g/dl
  • pregnancy
  • metallic implants or a pacemaker
  • limb amputation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    BIA REST

    BIA DW assessment

    Device: BIA DW

Interventions

  • DeviceBIA DW

    All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).

    Also known as: BIA Resistance Stabilization Test (REST)

06

What researchers measure

Primary outcomes

  1. Assessment of the gold standard method for the measurement of DW (in kg) through the comparison of clinical DW (as determined by means of a validated clinical score) and BIA DW (measurement of the resistance in kilohertz).

    Time frame: up to 4 weeks

07

Study locations

2 of 2 sites recruiting
  • Nephrology and dialysis unit Miulli General Hospital
    Acquaviva delle Fonti, Bari 70100, Italy
    Recruiting
  • Divisionof Nephrology
    Solofra, Italy
    Recruiting
    • Biagio Di Iorio, MD · Contact
08

References and documents

Publications

  • Basile C, Libutti P, Lisi P, Rossi L, Lomonte C. Probing the dry weight by bioimpedance: the resistance stabilization test. J Nephrol. 2015 Aug;28(4):517-20. doi: 10.1007/s40620-014-0159-8. Epub 2014 Dec 6. PubMed 25480486 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02606955
Lead sponsor
Miulli General Hospital
Responsible party
Carlo Basile, M.D. (Scientific Director of the Division of Nephrology, Miulli General Hospital) — Principal investigator
First posted
Nov 17, 2015
Start date
Feb 2015
Primary completion
Mar 2016 (estimated)
Completion
Dec 2016 (estimated)
Last update
Nov 17, 2015

Study contacts

Valentina Vigo, MD
Contact
vigovale2@libero.it
0803054496
Piero Lisi, MD
Contact
pierolisi76@libero.it
0803054347
Carlo Basile, MD
principal investigator · Mulli General Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion